Financing

#Financing #Funding #Immune system #IMU Biosciences

IMU Biosciences raises $53m to expand disease platform

IMU Biosciences has raised $53 million in a Series A financing round, pledging to use the funds to change understanding, diagnosis and treatment of disease. The biotechnology company has built what it claims to be the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026… Read More

#Business & Investment #News

Child with eczema
#Apogee Therapeutics #Dermatology #Financing

Apogee secures $1.3b to advance dermatitis treatment

Apogee Therapeutics has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialisation of zumilokibart.  Combined with company’s current total cash of $1.3 billion, the company… Read More

#Business & Investment #News

#CNS #Financing #Gene therapy #Latus Bio

Latus Bio announces $97 million series A financing

Gene therapy company Latus Bio has closed a $97 million Series A financing to support its therapeutics pipeline.   The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund. … Read More

#Business & Investment #News

#Biotech #Drug discovery #Financing #Oncology

Laigo Bio raises $17m to advance oncology pipeline  

Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million.   Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will… Read More

#Business & Investment #News

Heart monitor
#Biotech #Financing #Heart failure #Italy

NanoPhoria builds on record-breaking financing round

NanoPhoria Bioscience has announced the second closing of its series A financing round, including a €15 million equity investment from the European Innovation Council (EIC) Fund. The company recently received the largest ever Series A financing round in Italian biotech history, Alongside the EIC, NanoPhoria also received… Read More

#Business & Investment #News

Desmoid tumour
#Financing #Oncology #Parabilis Medicines

Parabilis Medicines announces oversubscribed $305m financing

Oncology biopharmaceutical company Parabilis Medicines has announced the successful closing of a $305 million Series F financing.  The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a… Read More

#Business & Investment #Cancer Research #News

#Antibody engineering #Financing #Nuclera

Nuclera raises $87m to advance antibody engineering 

Biotechnology company Nuclera has extended its Series C financing to $87 million to advance antibody engineering.  The financing round, led by Elevage Medical Technologies and Jonathan Milner, was extended by $12 million following earlier investment worth $75 million.  The funding is set to support Nuclera’s development of eProtein discovery for full-format antibody expression, purification and… Read More

#Business & Investment #News

#Biotech #Financing #Investment

$100m fund set up to invest in biotech companies 

Investment manager Arkin Capital has closed a $100 million financing round to set up Arkin Bio Ventures III, a $100m fund aimed at investing in biotech companies.  Arkin Bio Ventures III will back 10 to 12 pre-clinical to early clinical-stage biotech companies, developing transformative therapies in areas… Read More

#Business & Investment #News

Cancer cells
#EpiBiologics #Financing #Non-small cell lung cancer (NSCLC) #Oncology

Biotech startup raises $107m to advance oncology candidates 

Biotech startup EpiBiologics has raised $107 million Series B financing to support its pipeline of novel bispecific antibodies.  The financing, co-led by Google Ventures and Johnson & Johnson, will be used to advance candidate EPI-326 into a first-in-human clinical trial for treatment of EGFR-driven lung cancer and head and… Read More

#Business & Investment #News

#Biotech #Financing #Metabolic diseases #Obesity

Alveus raises $160m to progress weight loss candidate  

Biotechnology company Alveus Therapeutics has raised $159.8 million to advance its next-generation therapies for obesity and metabolic diseases.  Proceeds from the Series A financing will support Phase II clinical development of ALV-100, the company’s lead programme, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly… Read More

#Business & Investment #News

Neurodegenerative disorders
#Financing #Metabolic diseases #Neurodegenerative disorders #Novel therapeutics

Soley Therapeutics raises $200m to advance oncology leads 

Biotechnology company Soley Therapeutics has raised $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into clinic.  It is believed Soley intends to use the funds to support its work filing investigational new drug (IND) applications and its… Read More

#Business & Investment #News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Clinical trial #Financing

Vyriad raises $85m to advance CAR-T candidate to clinic 

Biotechnology company Vyriad has closed the final $25 million tranche of its Series B financing round to advance the company’s in vivo CAR-T candidate to clinic.  VV169 has been developed by Vyriad for the treatment of patients with relapsed or treatment-refractory multiple myeloma. The treatment is one of the first in… Read More

#Business & Investment #News